First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
Background This study assessed dolutegravir pharmacokinetics in HIV-infected infants receiving twice-daily (BID) dolutegravir with rifampicin-based tuberculosis (TB) treatment compared to once-daily (OD) dolutegravir without rifampicin. [...]
